Prevalence of peripheral neuropathy in pre-diabetes: a systematic review by Kirthi, Varo et al.
BMJ Open Diab Res Care 2021;9:e002040. doi:10.1136/bmjdrc-2020-002040
Open access 
1
Prevalence of peripheral neuropathy in 
pre- diabetes: a systematic review
Varo Kirthi   ,1,2 Anugraha Perumbalath,3 Emily Brown,3 Sarah Nevitt,4 
Ioannis N Petropoulos,5 Jamie Burgess,3 Rebecca Roylance,6 
Daniel J Cuthbertson,3 Timothy L Jackson,1,2 Rayaz A Malik   ,5,7 
Uazman Alam3,8,9
For numbered affiliations see 
end of article.
Correspondence to
Dr Uazman Alam;  
 Uazman. Alam@ liverpool. ac. uk
Dr Varo Kirthi;  v. kirthi@ nhs. net
To cite: Kirthi V, Perumbalath A, 
Brown E, et al. Prevalence of 
peripheral neuropathy in pre- 
diabetes: a systematic review. 
BMJ Open Diab Res Care 
2021;9:e002040. doi:10.1136/
bmjdrc-2020-002040
 ► Supplemental material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjdrc- 2020- 002040).
Received 25 November 2020
Revised 26 January 2021
Accepted 22 February 2021
Review
Pathophysiology/complications
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
There is growing evidence of excess peripheral neuropathy 
in pre- diabetes. We aimed to determine its prevalence, 
including the impact of diagnostic methodology on 
prevalence rates, through a systematic review conducted 
according to Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses guidelines. A comprehensive 
electronic bibliographic search was performed in MEDLINE, 
EMBASE, PubMed, Web of Science and the Cochrane 
Central Register of Controlled Trials from inception to June 
1, 2020. Two reviewers independently selected studies, 
extracted data and assessed risk of bias. An evaluation 
was undertaken by method of neuropathy assessment. 
After screening 1784 abstracts and reviewing 84 full- text 
records, 29 studies (9351 participants) were included. 
There was a wide range of prevalence estimates (2%–
77%, IQR: 6%–34%), but the majority of studies (n=21, 
72%) reported a prevalence ≥10%. The three highest 
prevalence estimates of 77% (95% CI: 54% to 100%), 71% 
(95% CI: 55% to 88%) and 66% (95% CI: 53% to 78%) 
were reported using plantar thermography, multimodal 
quantitative sensory testing and nerve conduction tests, 
respectively. In general, studies evaluating small nerve 
fiber parameters yielded a higher prevalence of peripheral 
neuropathy. Due to a variety of study populations and 
methods of assessing neuropathy, there was marked 
heterogeneity in the prevalence estimates. Most studies 
reported a higher prevalence of peripheral neuropathy in 
pre- diabetes, primarily of a small nerve fiber origin, than 
would be expected in the background population. Given 
the marked rise in pre- diabetes, further consideration 
of targeting screening in this population is required. 
Development of risk- stratification tools may facilitate 
earlier interventions.
INTRODUCTION
There is an enormous global burden of pre- 
diabetes, currently estimated to affect 374 
million people worldwide and projected to 
increase to 548 million (8.6% of the global 
adult population) by 2045.1 For pre- diabetes 
alone, the economic burden in the USA 
is greater than $43 billion. Pre- diabetes is 
associated with an increased incidence of 
diabetes- specific microvascular and macro-
vascular complications,2 and an increase in 
cardiovascular events and all- cause mortality,3 
compared with age- matched and body mass 
index (BMI)- matched people with normal 
glucose tolerance (NGT). Indeed, the excess 
risks of a major event (defined as fatal/
non- fatal cardiovascular disease or all- cause 
mortality) were 17% and 12% based on 
WHO and American Diabetes Association 
(ADA) criteria, respectively.3 End- organ 
complications of hyperglycemia may there-
fore be apparent prior to the diagnosis of 
type 2 diabetes.4 Unfortunately, people with 
pre- diabetes and concomitant microvascular 
disease are also more likely to develop type 
2 diabetes.5 Furthermore, the prevalence 
of diabetic peripheral neuropathy (DPN) 
has been reported as high as 35% (95% CI: 
15% to 55%) at the time of diagnosis of type 
2 diabetes, suggestive of an early subclinical 
disease phase.6
In the Toronto international consensus for 
DPN, a definite diagnosis requires at least one 
symptom and/or at least one sign of neurop-
athy and abnormality in nerve conduction 
studies (NCS).7 However, abnormalities in 
NCS which assess large myelinated nerve 
fibers that subserve touch, proprioception, 
vibration and motor function are later mani-
festations of DPN.8 By contrast, small nerve 
fiber deficits affecting unmyelinated or thinly 
myelinated C and Aδ nerve fibers involved 
in thermal, pain and autonomic function 
are thought to occur much earlier in DPN.9 
The precise natural history of small and large 
nerve fiber disease however is still unknown.
Although several studies have reported 
peripheral neuropathy in pre- diabetes, data 
in this area are conflicting, with some studies 
showing a high prevalence of peripheral 
neuropathy,10 11 and others suggesting a low 
prevalence.12–14 In pre- diabetes, continuous 
or episodic pain is often an early manifesta-
tion in the absence of a clinically detectable 
neuropathy, suggestive of small nerve fiber 
deficits. Indeed, skin biopsy and corneal 
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confocal microscopy (CCM), both techniques that can 
quantify early small nerve fiber damage, are abnormal in 
pre- diabetes.15 16 Further evidence of a lack of large fiber 
involvement is seen in studies using NCS, showing no 
difference when people with pre- diabetes are compared 
with those with NGT.12–14
In addition to NCS and CCM, several screening and 
diagnostic tests are available to assess DPN, including 
physical examination, quantitative sensory testing (QST) 
and skin biopsy, with a range of sensitivities and speci-
ficities.17 The National Institute for Health and Care 
Excellence in the UK recommends vibration perception 
testing using a 128 Hz tuning fork together with a 10 g 
Semmes- Weinstein monofilament for the screening of 
DPN. However, these tests identify advanced DPN at a 
late, irreversible and pre- ulcerative stage of the diabetic 
foot.18
This systematic review aimed to determine the prev-
alence of peripheral neuropathy in adults with pre- 
diabetes and to evaluate how prevalence estimates are 
influenced by the method of neuropathy assessment. We 
hypothesise that the diagnostic yield will be determined 
by the ability of the assessment tool to detect small nerve 
fiber abnormalities.
METHODS
The protocol for this systematic review was developed 
using Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses (PRISMA) guidelines and registered 
prospectively with the PROSPERO database of systematic 
reviews (ID: CRD42017080726).
Search strategy
The following electronic bibliographic databases were 
searched: MEDLINE (access via OVID), EMBASE (access 
via OVID), PubMed, Web of Science and the Cochrane 
Register of Controlled Trials, from inception until June 
1, 2020. The search strategy was independently reviewed 
by an expert information specialist using the Peer 
Review of Electronic Search Strategies checklist and the 
MEDLINE search terms are included in online supple-
mental appendix 1. Additional articles were identified 
by searching the references of included studies and 
other review articles identified during the course of the 
searches. Results from the database searches were merged 
using an electronic reference manager (EndNote V.X9, 
Clarivate Analytics, Philadelphia, Pennsylvania, USA) to 
facilitate removal of duplicates. Relevant publications 
were retrieved manually from hard copies of journals, if 
electronic access was not available.
Participants, eligibility and setting
Inclusion criteria were adults over 18 years of age who 
have pre- diabetes defined either by WHO or ADA criteria. 
Population- based cohort or cross- sectional studies from 
any country in any setting were considered, provided they 
were reported in English and reported prevalence data 
for peripheral neuropathy. Studies were excluded if they 
failed to report an independent pre- diabetes group or 
the prevalence of peripheral neuropathy. Studies exclu-
sively investigating other forms of neuropathy, including 
autonomic neuropathy, were considered outside the 
scope of this review and excluded.
Study selection
Two reviewers independently screened titles and abstracts 
from the searches. Any disagreements were resolved by 
discussion with the senior reviewer (UA). All potentially 
eligible articles were selected for independent full- text 
assessment by two reviewers. Disagreements between the 
reviewers were resolved by the senior reviewer (UA), in 
deciding if an article was eligible for inclusion. A PRISMA 
flow chart of the selection process is shown in online 
supplemental appendix 2.
Data collection process
Two reviewers independently extracted data using pre- 
piloted forms. Data extracted included: (1) date and 
country of study, (2) study design, (3) age, sex and 
ethnicity of participants, (4) definition of pre- diabetes, 
(5) method(s) of assessing peripheral neuropathy, (6) 
study groups and sizes, (7) overall sample size, and (8) 
prevalence numbers and estimates.
Risk of bias assessment
A modified critical appraisal tool specifically developed 
for assessing risk of bias in prevalence studies was used 
in all included articles and is included in online supple-
mental appendix 3.19 Quality assessment was conducted 
independently by two reviewers and any disagreements 
were resolved by the senior reviewer (UA).
Data analysis
Statistical heterogeneity between included studies was 
assessed using the I2 statistic. Clinical heterogeneity was 
assessed based on study design, population and methods 
used to measure peripheral neuropathy. Due to high 
clinical and statistical heterogeneity (I2 >90%), a subse-
quent meta- analysis was not conducted. Characteristics of 
included studies and prevalence estimates are presented 
in summary tables and narrative text. Further evaluation 
of the included studies was undertaken by comparing 
methods of neuropathy assessment to assess differences 
in prevalence estimates.
RESULTS
Study and participant characteristics
After removal of duplicate entries, 1526 unique records 
were identified from the electronic database searches. 
Titles and abstracts were reviewed against the eligi-
bility criteria and 84 records were selected for full- text 
review. From these records, 29 studies with 9351 partic-
ipants fulfilled the eligibility criteria and were included 
in the final review. Details of the selected articles and 
reasons for exclusion after full- text review are shown in 
online supplemental appendix 2. Characteristics of the 
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included studies are presented in Electronic Supple-
mentary Material (ESM) (table 1). Nine of these studies 
were conducted in single European countries,16 20–27 
five in the USA,12–14 28 29 five in China30–34 and two in 
Japan.35 36 One study was conducted across nine coun-
tries.37 The remaining studies were each conducted in 
Brazil,38 Australia,39 Egypt,40 India,41 Canada,11 United 
Arab Emirates42 and Turkey.43 Most studies had a cross- 
sectional population- based or hospital- based design and 
one was a double- blind randomized controlled trial. The 
age of included participants varied widely between 20 
and 83 years. However, of the 19 studies that reported an 
average age of included participants, over half (10 of 19, 
53%) reported a mean age above 55 years. Gender ratios 
also varied widely and were reported by the majority of 
included studies (25 of 29, 86%). Methods of assessing 
neuropathy and criteria used for defining pre- diabetes 
are presented in ESM (table 1); 22 studies (76%) used 
WHO criteria to define pre- diabetes.
Risk of bias
Overall quality scores of the reviewed studies and points 
scored for each item in the critical appraisal tool are 
provided in table 1. With the exception of Asghar et 
Table 1 Summary of the methodological quality assessment for each study using the Hoy et al19 risk of bias tool
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Total
Asghar et al16 1 1 1 1 0 0 0 0 0 4
Balbinot et al38 0 0 1 1 0 0 0 0 0 2
Barr et al39 0 0 1 1 0 0 0 0 0 2
Bongaerts et al24 1 0 1 0 0 0 0 0 0 2
Callaghan et al29 0 1 1 1 0 0 0 0 0 3
Callaghan et al32 0 0 0 0 0 0 0 0 1 1
De Neeling et al20 1 0 0 1 0 0 0 0 0 2
Dimova et al25 1 0 1 1 0 0 0 0 0 3
Dyck et al14 0 0 0 1 0 0 0 0 0 1
Franklin et al28 0 0 0 0 0 0 0 0 0 0
Fujimoto et al12 1 0 1 1 0 0 0 0 0 3
Fujimoto et al13 1 0 1 1 0 0 0 0 0 3
Gabriel et al37 1 0 0 1 0 0 0 0 0 2
Herman et al40 0 0 0 1 0 0 0 0 0 1
Kannan et al41 0 1 1 1 0 0 0 0 0 3
Kopf et al27 1 1 1 0 0 0 0 0 0 3
Kurisu et al36 0 0 1 1 0 0 0 0 0 2
Lee et al11 0 1 1 0 0 0 0 0 0 2
Lin et al30 0 0 0 1 0 0 0 0 0 1
Liu et al33 1 0 1 1 0 0 0 0 0 3
Lu et al31 0 1 1 1 0 0 0 0 0 3
Németh et al26 0 0 1 1 0 0 0 0 0 2
Oohashi et al35 0 0 1 1 0 0 1 0 0 3
Saadi et al42 0 0 1 1 0 0 0 0 0 2
Sahin et al43 0 1 1 1 0 0 0 0 0 3
Zeng et al34 1 0 1 1 0 0 0 0 0 3
Ziegler et al21 1 0 0 1 0 0 0 0 0 2
Ziegler et al10 0 0 0 1 0 0 0 0 0 2
Ziegler et al23 1 0 0 1 0 0 0 0 0 2
Please see online supplemental appendix 2 for full tool. Q1: Was the study’s target population a close representation of the national 
population in relation to relevant variables, for example, age, sex, occupation? Q2: Was the sampling frame a true or close representation 
of the target population? Q3: Was some form of random selection used to select the sample, or was a census undertaken? Q4: Was the 
likelihood of non- response bias minimal? Q5: Were data collected directly from the subjects (as opposed to a proxy)? Q6: Was an acceptable 
case definition used in the study? Q7: Was the study instrument that measured the parameter of interest shown to have reliability and 
validity? Q8: Was the same mode of data collection used for all subjects? Q9: Were the numerator(s) and denominator(s) for the parameter of 
interest appropriate? Overall risk of bias score: 0–3=low risk, 4–6=moderate risk, 7–9=high risk.
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al16 which scored 4 (moderate risk of bias), all of the 
remaining studies were deemed at ‘low’ risk of bias 
(total score ≤3). The most common issues were: (1) the 
likelihood of a non- response bias, particularly where 
participant selection and response rates were not clearly 
reported (24 studies), (2) failure to undertake a census 
or use a form of random selection to obtain the sample 
(19 studies) and (3) the target population of the study 
not being representative of the national population (12 
studies).
Overall prevalence
Figure 1 shows the prevalence of peripheral neuropathy 
with 95% CIs for the population with pre- diabetes in each 
study. Prevalence estimates varied widely, from 2% (95% 
CI: 0% to 4%) in a study conducted in the USA to 77% 
(95% CI: 54% to 100%) in a study conducted in Brazil 
(IQR for all included studies: 6%–34%).13 38 The majority 
of studies (n=21, 72%) reported prevalence estimates 
≥10%. Due to a high level of heterogeneity (I2 >90%), 
pooled prevalence estimates were not calculated.
Figure 1 Summary of prevalence estimates of peripheral neuropathy in pre- diabetes for all included studies. Prevalence 
estimates reported with 95% CIs and primary method used to assess peripheral neuropathy. For three studies (Fujimoto,12 
Fujimoto,13 and Dyck14), the 95% confidence intervals around the prevalence estimate were wide and the lower bound of the 
confidence interval was estimated to be less than 0. This is due to the small numbers used in the estimation of prevalence (in 
the prevalence group) and the standard error (SE) of prevalence (where SE = square root [p(1- p)/n], where p is the prevalence 
of peripheral neuropathy as a proportion and n is the total number of people in the study or study group), and the uncertainty 
of the SE is reflected within the wide confidence intervals. The lower bounds of these negative confidence intervals should be 
considered to be 0. ATR, Achilles tendon reflex; CCM, corneal confocal microscopy; CPT, current perception threshold; DNES, 
Diabetic Neuropathy Examination Score; ESC, electrochemical skin conductance; MNSI, Michigan Neuropathy Screening 
Instrument; NCS, nerve conduction studies; NCT, nerve conduction test; NDS, Neuropathy Disability Score; NIS, Neuropathy 
Impairment Score; NSS, Neuropathy Symptom Score; NTSS, Neuropathy Total Symptom Score; PPS, Pressure Perception 
Score; PS, pressure sensation; PTR, patellar tendon reflex; QST, quantitative sensory testing; QTS, quantitative tactile 
stimulation; TCSS, Toronto Clinical neuropathy Scoring System; TDT, thermal discrimination threshold; TRI, Thermal Recovery 
Index; VP, vibration perception; VPT, vibration perception threshold; VS, vibration sensation.
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Methods of assessment
Studies used a combination of clinical histories, ques-
tionnaires, physical examinations and quantitative assess-
ments to assess peripheral neuropathy. One study failed to 
provide information on the method of neuropathy assess-
ment.35 The heterogeneity and wide variation in preva-
lence estimates were in part due to varying methods of 
neuropathy assessment. Therefore, a narrative summary 
is presented below.
Studies using quantitative techniques: seven studies 
used quantitative techniques alone to assess peripheral 
neuropathy.12–14 20 26 34 40 Eleven studies presented data 
from NCS,12–14 25–27 33 34 36 41 43 while two measured quanti-
tative vibration sensation.24 40 Four studies assessed small 
nerve fiber function using a variety of methods including 
CCM, electrochemical skin conductance (ESC), plantar 
thermography and contact heat pain- evoked poten-
tials.16 33 37 38
NCS: prevalence estimates for peripheral neuropathy 
with conventional NCS varied between 2% and 65% using 
a variety of techniques.13 34 However, the four studies 
that measured nerve conduction parameters alone all 
reported peripheral neuropathy prevalence estimates of 
6% or less.12–14 25 Németh et al26 used the Neurometer R 
device to evaluate the current perception threshold, a 
composite of small and large fiber dysfunction, reporting 
a prevalence estimate of 58%.
Quantitative vibration sensation: from the two studies 
that measured quantitative vibration sensation, prev-
alence estimates were 14% and 10%, using different 
methods.24 40 In the KORA F4 Study, Bongaerts et al24 
defined peripheral neuropathy as the presence of bilat-
erally impaired foot- vibration perception and/or foot- 
pressure sensation, while Herman et al40 reported a lower 
prevalence estimate, assessing vibration perception using 
a forced choice algorithm.
Quantitative small nerve fiber assessment: the four studies 
assessing small nerve fiber function also reported a range 
of prevalence estimates. Two studies assessed thermal 
sensation, with Balbinot et al38 reporting a prevalence 
of 77% with plantar thermography while Liu et al33 
reported a prevalence of 18% by measuring contact heat 
pain- evoked potential. CCM demonstrated that 41% of 
participants with pre- diabetes had evidence of peripheral 
neuropathy, while ESC showed the prevalence of severe 
neuropathy, defined as ESC <50 µs in feet or <40 µs in the 
hands, was 5%.16 37
Studies using physical examinations alone: two studies 
used physical examination alone as the primary method 
of peripheral neuropathy assessment. De Neeling et 
al20 used absence of vibration sensation at the big toe 
as an indicator of peripheral neuropathy, while Saadi et 
al42 used the Diabetic Neuropathy Examination Score. 
The prevalence estimates reported were 16% and 12%, 
respectively.
Studies using a combination of methods: the remaining 
studies used a combination of questionnaires, physical 
examination and quantitative assessment. Franklin et 
al28 used a combination of history, physical examination 
and quantitative vibration threshold testing, reporting 
a peripheral neuropathy prevalence of 11%, which was 
higher than in participants with NGT (3.9%) but lower 
than in participants with diabetes (25.8%). Eleven studies 
used a combination of questionnaires and physical exam-
ination. Barr et al39 and Lu et al31 used the Neuropathy 
Symptom Score (NSS) and Neuropathy Disability Score 
(NDS), while Callaghan et al29 used the Toronto consensus 
definition of ‘probable neuropathy’, which requires two or 
more of neuropathy symptoms, abnormal sensory exam-
ination or abnormal reflexes. The Michigan Neuropathy 
Screening Instrument (MNSI) was the most commonly 
used scoring tool, detecting a peripheral neuropathy prev-
alence ranging from 9% to 49% across six studies.11 21–23 33 43
Age, gender and ethnicity
Although age- specific and gender- specific prevalence 
estimates were not reported, two studies by the same 
authors separately reported similar prevalence figures 
in Japanese- American men and women using the same 
method of assessment.12 13 Despite the wide geographic 
variation in where studies were conducted, none of the 
included studies reported ethnicity- specific prevalence 
estimates of peripheral neuropathy.
Study population
Although estimates of peripheral neuropathy prevalence 
varied widely between study populations, the vast majority 
of hospital- based cross- sectional studies reported esti-
mates ≥20% (10 of 12, 83%), in contrast to population- 
based studies (2 of 15, 13%). The three highest prevalence 
estimates of 77% (95% CI: 54% to 100%), 71% (95% CI: 
55% to 88%) and 65% (95% CI: 53% to 78%) were all 
reported in hospital- based studies using plantar ther-
mography, long QST and nerve conduction tests, respec-
tively.27 34 38 Further analysis by geographic region was 
limited by differing methods of neuropathy assessment.
Pre-diabetes subtype
Due to varying methods of assessment, a pooled anal-
ysis could not be performed by pre- diabetes subtype. 
However, four studies presented separate prevalence esti-
mates for impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT). In two similar studies defining 
neuropathy as an MNSI score ≥2, Ziegler et al21 22 reported 
a higher prevalence in IGT (13% and 25%) than IFG 
(11% and 9%, respectively). Based on a Toronto Clinical 
neuropathy Scoring System score ≥2, Lin et al30 reported 
a higher prevalence in combined IFG/IGT (19%) than 
either isolated IFG (16%) or IGT (13%). Similarly, 
using vibration perception and perception sensation, 
Bongaerts et al24 also reported a higher prevalence of 
peripheral neuropathy in combined IFG/IGT (24%) 
than either isolated IFG (6%) or IGT (15%).
DISCUSSION
Summary of main results
The majority of studies (21 of 29, 72%) in this system-
atic review reported a ≥10% prevalence of peripheral 
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neuropathy in pre- diabetes, although with figures varying 
widely between 2% and 77%, in part due to diagnostic 
methodology. This is higher than the background preva-
lence of peripheral neuropathy reported in the general 
population of 1%–3% (increasing to 7% in the elderly).44 
Prevalence estimates were consistently higher than partic-
ipants with NGT, within the same study. From the data 
evaluated in this review, pre- diabetes is a risk factor for 
chronic axonal polyneuropathy, consistent with an initial 
involvement of small nerve fibers. This is a major cause 
of neuropathic pain and associated morbidity, as well 
as being an initiating factor in diabetic foot ulceration. 
Smith and Singleton have suggested that pre- diabetes 
is common in patients with peripheral neuropathy and 
that it occurs in approximately 40% of patients with an 
idiopathic etiology.45 Early microvascular complications 
have been reported by other authors, and our recently 
published systematic review has also demonstrated an 
excess of cardiac autonomic neuropathy in pre- diabetes.46
Comparisons with previous data
Understanding the natural history of DPN and periph-
eral neuropathy in pre- diabetes is vital to determine 
the optimal screening approach. A systematic review 
conducted in 2011 found a significant proportion of 
participants with IGT have mainly small nerve fiber defi-
cits.47 In vivo studies support the hypothesis that small 
nerve fiber deficits are the earliest manifestations of 
peripheral neuropathy in pre- diabetes.28 43 Evidence of 
early small nerve fiber pathology in IGT also supports 
this hypothesis. Our study using CCM reported that small 
nerve fiber deficits predicted progression from IGT to 
diabetes, and interestingly, improvement of small nerve 
fiber deficits in participants with IGT who reverted to 
NGT.5 These objectively quantifiable improvements in 
corneal and intraepidermal nerve morphology that occur 
in response to changes in glucose tolerance are also in 
keeping with improvements in large nerve fiber function 
with metabolic control.48
The principal difficulty in appraising the current liter-
ature is the variety of diagnostic methodologies used to 
identify neuropathy, and their relative abilities to assess 
earlier small nerve fiber versus later large nerve fiber 
damage. For instance, methods used in annual diabetic 
foot screening programs (10 g monofilament and 
128 Hz tuning fork) have poor sensitivity in the detec-
tion of DPN and aim to identify patients at high risk of 
foot ulceration, hence they do not identify early nerve 
damage.49 While no study solely relied on a questionnaire 
or patient history to assess peripheral neuropathy, several 
studies used a combination of screening tools, physical 
examination and quantitative tests to improve diagnostic 
sensitivity. For instance, two studies used the NSS ques-
tionnaire in combination with physical examination (Lui 
et al and Barr et al), with both studies reporting low preva-
lence rates of peripheral neuropathy. The NSS is thought 
to poorly reflect the progression of DPN,50 despite having 
a higher diagnostic sensitivity (83%) than the Diabetic 
Neuropathy Score (64%).51 Devigili et al52 have previ-
ously shown that a combination of methods, including 
clinical abnormalities and small nerve fiber evaluation 
using QST and skin biopsy, offers a sensitivity of 92.5% 
for small nerve fiber neuropathy of any cause.
Small nerve fiber tests for a small nerve fiber disease
Gain of small nerve fiber sensory function has been 
demonstrated in pre- diabetes. Kopf et al27 reported a 
prevalence of mechanical hyperalgesia as high as 33%, 
although whether this is due to central sensitisation, 
small nerve fiber dysfunction or a combination of both 
is debated. However, there is consensus that large nerve 
fiber involvement only occurs with increasing dura-
tion of diabetes, hence there is a paucity of large nerve 
fiber dysfunction in pre- diabetes, in the early stages of 
dysglycemia. Dyck et al14 reported a low prevalence of 
peripheral neuropathy in IGT similar to individuals 
with normoglycemia, when performing primarily large 
nerve fiber diagnostics (NCS). Unfortunately, current 
consensus endpoints of neuropathy lack sensitivity to 
capture early small nerve fiber abnormalities prior to the 
development of overt large nerve fiber pathology. Many 
of these methods are either invasive (eg, skin biopsy) or 
have repeatedly failed as surrogate endpoints of thera-
peutic efficacy in clinical trials of DPN (eg, NCS and 
QST).
On the contrary, the German Research Network on 
Neuropathic Pain QST protocol accurately identifies 
patterns of small nerve fiber deficits.53 However, applica-
tion of the full battery of QST tests is time- consuming 
and not feasible in routine clinical practice. While skin 
biopsy is still considered to be the reference standard for 
the identification of small nerve fiber pathology, mass 
screening with repeated biopsies is not feasible. CCM, 
on the other hand, can provide detailed quantification 
of small nerve fibers and predict the development and 
progression of DPN.54 55 CCM also has increased diag-
nostic ability when combined with artificial intelligence- 
based deep learning algorithms and has potential to be 
implemented on a population basis.56
The detection of early peripheral neuropathy in pre- 
diabetes allows for a multifaceted interventional approach 
to halt the progression or even reverse neuropathic defi-
cits. Unfortunately, current screening methods detect 
advanced neuropathy, thus any putative interventions are 
often ineffective. From these data, NCS alone may not 
be sufficiently sensitive to identify subclinical peripheral 
neuropathy in populations with pre- diabetes.15
A number of cross- sectional studies have demon-
strated the coexistence of small and large nerve fiber 
abnormalities in DPN.5 49 57 58 In the ADDITION Study 
(Anglo- Danish- Dutch study of Intensive Treatment In 
peOple with screeN- detected diabetes), CCM could not 
differentiate the absence or presence of DPN in type 
2 diabetes.59 Additionally, Ziegler et al60 reported that 
nerve fiber loss in recently diagnosed type 2 diabetes, 
detected by both skin biopsy and CCM, occurred in 
7BMJ Open Diab Res Care 2021;9:e002040. doi:10.1136/bmjdrc-2020-002040
Pathophysiology/complications
largely different populations of patients, suggesting a 
disparate manifestation of small nerve fiber pathology. 
There was also a reduction in NCS parameters in a 
subgroup suggestive of large nerve fiber disease.60 The 
precise natural history of DPN remains to be eluci-
dated as at present, the relative contributions and onset 
of small and large nerve fiber disease remain poorly 
understood. This is primarily due to a paucity of natural 
history studies examining the relative contributions of 
small and large nerve involvement in people at high risk 
of insulin- resistance states, as they progress from NGT 
through to pre- diabetes, newly diagnosed diabetes and 
established diabetes.
Despite these limitations, Asghar et al16 did show a 
high prevalence of small nerve fiber pathology (41%) 
when assessed using CCM, with comparable reductions 
in intraepidermal nerve fiber density. Future screening 
and prevalence studies in pre- diabetes should therefore 
include a validated, reproducible method for detecting 
small nerve fiber pathology, such as CCM. Importantly, 
diet and exercise counseling in pre- diabetes results in 
cutaneous re- inervation and improved pain.15
Prevalence estimates vary by diagnostic tests
The MNSI was used as the primary method of assessment in 
six of the included studies. Balbinot et al38 compared MNSI 
with Thermal Recovery Index, electromyography and inter-
digital anisothermal technique (IDA). The prevalence of 
peripheral neuropathy in pre- diabetes was 77%, 15% and 
77%, respectively; while MNSI failed to identify peripheral 
neuropathy in any of the participants, even in cases with an 
abnormal nerve conduction velocity. IDA, a measure of small 
nerve fiber dysfunction, was considered the most appropriate 
test to identify peripheral neuropathy in pre- diabetes by the 
study authors. Similarly, Sahin et al43 found the prevalence of 
peripheral neuropathy to be higher with NCS (21%) than 
with MNSI (16%). Kopf et al27 noted the addition of the 
NDS improved the sensitivity of short QST (testing thermal 
parameters alone). This supports the argument that a combi-
nation of tests improves sensitivity, compared with a single 
scoring tool or test.
Prevalence estimates and diagnostic test cut-off values
Another challenge with interpreting prevalence data 
was the variety of cut- off scores used to define peripheral 
neuropathy on questionnaires and composite scoring 
methods. Defining peripheral neuropathy as an MNSI score 
of ≥2, Ziegler et al23 reported a prevalence of 31%; however 
the same study reported a lower prevalence of 20% when 
peripheral neuropathy was defined as an MNSI score ≥3. 
The authors also reported a peripheral neuropathy preva-
lence when using MNSI in combination with a 10 g mono-
filament test: with an MNSI score ≥2, the prevalence in 
pre- diabetes was 35% compared with 21% with an MNSI 
score ≥3. The variability of these prevalence estimates high-
lights the difficulty in interpreting data even from the same 
scoring tool.
Pathophysiology of small nerve fiber deficits in pre-diabetes: 
IFG, IGT or both?
The etiology of dysglycemia may be of relevance to the 
development of peripheral neuropathy. In the MONICA/
KORA (Cooperative Health Research in the Region Augs-
burg) Study, the prevalence of peripheral neuropathy was 
greater in IGT than in participants with NGT.21 Out of 
195 participants with type 2 diabetes, 71 with IFG, 46 with 
IGT and 81 with normoglycemia, neuropathic pain was 
detected in 28%, 11%, 13% and 7%, respectively, which is 
consistent with preferential small nerve fiber involvement in 
groups with pre- diabetes.21 Bongaerts et al24 reported similar 
data with a higher prevalence in IGT (15%), even higher 
in combined IFG with IGT (24%), when compared with 
isolated IFG (6%). The annual incidence of type 2 diabetes 
in individuals with isolated IGT (4%–6%) and isolated IFG 
(6%–9%) is lower than in those with combined IFG and IGT 
(15%–19%).61 This suggests that isolated IFG and isolated 
IGT may differ in their pathophysiology, with an IFG–IGT 
co- diagnosis reflecting a much more severe disturbance of 
glycemic homeostasis, with a greater risk of progression to 
type 2 diabetes.
The site of insulin resistance in isolated IFG is predom-
inantly hepatic, whereas people with isolated IGT have 
greater muscle insulin resistance. Obesity and insulin resis-
tance result in a cascade of metabolic and pro- inflammatory 
effects which are self- reinforcing and lead to microvascular 
disease and peripheral nerve injury.62 Decreased skeletal 
muscle sensitivity to insulin leads to adipocytes increasing 
their uptake of glucose.62 This results in the release of free 
fatty acids and triglycerides, thus resulting in oxidative stress 
which is a major factor in the development of peripheral 
nerve injury.62 Mitofusin-2 (Mfn2), the gene responsible 
for Charcot- Marie- Tooth type 2A, encodes a mitochondrial 
protein that regulates mitochondrial metabolism and intra-
cellular signaling. Mfn2 mRNA is downregulated in type 2 
diabetes, upregulated in weight loss and is inversely propor-
tional to BMI in skeletal muscle.63 Mfn2 mutations are known 
to cause severe phenotypes of neuropathy in Charcot- Marie- 
Tooth type 2A.64
Limitations and future work
A number of methodological issues were identified, including 
the wide variability of sample size. Only four studies had pre- 
diabetes sample sizes greater than 1000 participants30–32 39; 
the remainder were smaller, with the smallest reporting only 
13 participants.38 Such small studies are at particular risk of 
reporting bias and overestimating the magnitude of periph-
eral neuropathy prevalence. Population bias also limited 
the generalisability of the prevalence data; many studies 
recruited participants from hospital clinics, which may not 
accurately represent the burden of pre- diabetes within 
the general population. We only included published data 
and limited studies to those in English language only. Due 
to a high level of clinical heterogeneity from the variety of 
diagnostic approaches used, and statistical heterogeneity 
from variations in study design and sampling methods, a 
meta- analysis could not be performed. Many studies failed 
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to report prevalence figures or reported the prevalence of 
pre- diabetes in individuals with peripheral neuropathy, 
therefore failing to meet the inclusion criteria for this review. 
Given the significant excess of peripheral neuropathy noted 
in the included studies, large prospective population- based 
and mechanistic studies are now required. Such studies 
should use standardized quantitative methods, evaluating 
small nerve fibers to accurately determine the prevalence of 
peripheral neuropathy and accurately delineate its patho-
physiology. Future research includes the development of 
risk- stratification tools to identify those most at risk of periph-
eral neuropathy in pre- diabetes, to ensure the feasibility of 
any proposed screening methods.
CONCLUSIONS
This systematic review reports a high prevalence of a primary 
axonal polyneuropathy in pre- diabetes. There is a need to 
develop risk- stratification tools to identify those most at risk 
of peripheral neuropathy. Future clinical trials are needed 
to explore the potential benefits of early interventions with 
novel pharmacotherapy, dietary and weight loss interven-
tions, such as low- calorie diets and multifactorial risk factor 
modification, in this at- risk population.
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